NasdaqGM - Delayed Quote • USD
Ligand Pharmaceuticals Incorporated (LGND)
At close: April 19 at 4:00 PM EDT
After hours: April 19 at 4:13 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 4 | 4 | 3 |
| Avg. Estimate | 0.83 | 1.02 | 4.45 | 5.6 |
| Low Estimate | 0.56 | 0.96 | 4.35 | 5.39 |
| High Estimate | 1.17 | 1.17 | 4.55 | 5.92 |
| Year Ago EPS | 2.28 | 1.42 | 6.09 | 4.45 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 4 | 4 | 5 | 4 |
| Avg. Estimate | 27.92M | 33.19M | 137.68M | 160.73M |
| Low Estimate | 23.38M | 29.93M | 134.3M | 153.8M |
| High Estimate | 31.61M | 35.3M | 141.3M | 170M |
| Year Ago Sales | 43.98M | -- | 131.31M | 137.68M |
| Sales Growth (year/est) | -36.50% | -- | 4.80% | 16.70% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | 0.89 | 0.64 | 0.61 | 0.66 |
| EPS Actual | 2.28 | 1.42 | 1.02 | 1.38 |
| Difference | 1.39 | 0.78 | 0.41 | 0.72 |
| Surprise % | 156.20% | 121.90% | 67.20% | 109.10% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | 0.83 | 1.02 | 4.45 | 5.6 |
| 7 Days Ago | 0.83 | 1.02 | 4.45 | 5.6 |
| 30 Days Ago | 0.83 | 1.02 | 4.45 | 5.6 |
| 60 Days Ago | 0.97 | 0.94 | 4.27 | 5.35 |
| 90 Days Ago | 0.85 | 1.02 | 4.28 | 5 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | LGND | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -63.60% | -- | -- | 1.60% |
| Next Qtr. | -28.20% | -- | -- | 10.50% |
| Current Year | -26.90% | -- | -- | 5.20% |
| Next Year | 25.80% | -- | -- | 13.30% |
| Next 5 Years (per annum) | 20.00% | -- | -- | 11.22% |
| Past 5 Years (per annum) | 9.76% | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Reiterates | Benchmark: Buy to Buy | 4/12/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 2/29/2024 |
| Reiterates | Benchmark: Buy to Buy | 12/13/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 9/19/2023 |
| Reiterates | Benchmark: Buy to Buy | 8/23/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 8/9/2023 |
Related Tickers
OABI OmniAb, Inc.
4.6700
+1.74%
ADMA ADMA Biologics, Inc.
6.27
+1.13%
LYEL Lyell Immunopharma, Inc.
2.2300
-4.29%
TVTX Travere Therapeutics, Inc.
5.72
-1.38%
KROS Keros Therapeutics, Inc.
58.28
-1.14%
QTTB Q32 Bio Inc.
22.49
-7.75%
KYMR Kymera Therapeutics, Inc.
33.97
-3.27%
MORF Morphic Holding, Inc.
27.99
+1.74%
ADCT ADC Therapeutics SA
4.7200
-0.84%
IONS Ionis Pharmaceuticals, Inc.
40.68
-0.32%